Response: Re: Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

P. C. Prorok, A. B. Miller, B. S. Kramer
2012 Journal of the National Cancer Institute  
We thank Dr Braillon and Dr Dubois for their comments. We share their concern that the use of PSA screening leads to overdiagnosis. In the PLCO trial, we estimate that approximately 21% of the screendetected prostate cancers were overdiagnosed, which was derived from the excess Notes
doi:10.1093/jnci/djs206 fatcat:glteh4h36bhjtbymtriusw4jfq